Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: A comparative cohort analysis between Western India and United Kingdom

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Pujari, Sanjay N ^a   Smith, Colette ^b   Makane, Abhimanyu ^a   Youle, Mike ^c   Johnson, Margaret ^c   Bele, Vivek ^a   Joshi, Kedar ^a   Dabhade, Digamber ^a   Bhagani, Sanjay ^c  

^a Institute of Infectious Diseases   (India)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

India; Nephrotoxicity; Tenofovir

Indexed keywords

TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SAFETY; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INDIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; UNITED KINGDOM; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; HIV INFECTIONS; KIDNEY DISEASES; MIDDLE AGED;

ADENINE; ADULT; ANTI-HIV AGENTS; COHORT STUDIES; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; INDIA; KIDNEY DISEASES; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES;

EID: 84898889996     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-173     Document Type: Article

References (20)

1. De WR, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One 2013, 8(5):e63623. 10.1371/journal.pone.0063623, 3665842, 23723990.
2. Antiretroviral therapy for HIV infection in adults and adolescents Recommendations for a public health approach: 2010 revision. 2010, http://www.who.int/hiv/pub/arv/adult2010/en/index.html. 2013.
3. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, 903 Study group Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292(2):191-201. 10.1001/jama.292.2.191, 15249568, 903 Study group.
4. Agbaji OO, Agaba PA, Idoko JA, Taiwo B, Murphy R, Kanki P, Ekong E. Temporal changes in renal glomerular function associated with the use of Tenofovir Disoproxil Fumarate in HIV-infected Nigerians. West Afr J Med 2011, 30(3):164-168.
5. Gayet-Ageron A, Ananworanich J, Jupimai T, Chetchotisakd P, Prasithsirikul W, Ubolyam S, Le Braz M, Ruxrungtham K, Rooney JF, Hirschel B, Staccato study group No change in calculated creatinine clearance after tenofovir initiation among Thai patients. J Antimicrob Chemother 2007, 59(5):1034-1037. 10.1093/jac/dkm064, 17376791, Staccato study group.
6. Manosuthi W, Prasithsirikul W, Tantanathip P, Chimsuntorn S, Nilkamhang S, Sungkanuparph S. Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting. Southeast Asian J Trop Med Public Health 2011, 42(3):643-650.
7. Kiertiburanakul S, Chaisiri K, Kasettratat N, Visuttimak P, Bowonwatanuwong C. Monitoring of Renal Function among HIV-Infected Patients Receiving Tenofovir in a Resource-Limited Setting. J Int Assoc Physicians AIDS Care (Chic ) 2011, 10(5):297-302. 10.1177/1545109711406735, 21606380.
8. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010, 51(5):496-505. 10.1086/655681, 20673002.
9. Ryom L, Mocroft A, Kirk O, Ross M, Reiss P, Fux CA, Morlat P, Moranne O, Smith C, El-Sadr W, Law M, Lundgren JD. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS 2014, 28(2):187-199. 10.1097/QAD.0000000000000042, 24361680.
10. Stohr W, Reid A, Walker AS, Ssali F, Munderi P, Mambule I, Kityo C, Grosskurth H, Gilks CF, Gibb DM, Hakim J, DART Trial team Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. Antivir Ther 2011, 16(7):1011-1020. 10.3851/IMP1832, 22024517, DART Trial team.
11. Bailey PK, Tomson CR, Kinra S, Ebrahim S, Radhakrishna KV, Kuper H, Nitsch D, Ben-Schlomo Y. Differences in estimation of creatinine generation between renal function estimating equations in an Indian population: cross-sectional data from the Hyderabad arm of the Indian migration study. BMC Nephrol 2013, 14:30. 10.1186/1471-2369-14-30, 3599554, 23379609.
12. Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. QJM 2014,
13. Pujari S, Dravid A, Gupte N, Joshix K, Bele V. Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India. J Int AIDS Soc 2008, 10(8):196. 10.1186/1758-2652-10-8-196, 2757396, 19825144.
14. Patel KK, Patel AK, Ranjan RR, Patel AR, Patel JK. Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India. Indian J Sex Transm Dis 2010, 31(1):30-34. 10.4103/0253-7184.68998, 3140146, 21808434.
15. Calcagno A, De Gonzalez RD, Simiele M, D'Avolio A, Tettoni MC, Salassa B, Orofino G, Bramato C, Libanore V, Motta I, Bigliano P, Orsucci E, DiPerri G, Bonora S. Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. Antimicrob Agents Chemother 2013, 57(4):1840-1843. 10.1128/AAC.02434-12, 3623307, 23380733.
16. Nishijima T, Gatanaga H, Komatsu H, Tsukada K, Shimbo T, Aoki T, Watanabe K, Kinai E, Honda H, Tanuma J, Yazaki H, Honda M, Teruya K, Kikuchi Y, Oka S. Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naive patients with HIV infection. PLoS One 2012, 7(1):e29977. 10.1371/journal.pone.0029977, 3252345, 22242194.
17. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S, California Collaborative Treatment Group 578 Team Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008, 197(1):102-108. 10.1086/524061, 18171292, California Collaborative Treatment Group 578 Team.
18. Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, Santoianni R, Lewis W. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 2011, 91(6):852-858. 10.1038/labinvest.2011.48, 3103636, 21403643.
19. Young J, Schafer J, Fux CA, Furrer H, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC, Swiss HIV Cohort S. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012, 26(5):567-575. 10.1097/QAD.0b013e32834f337c, 22398568.
20. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011, 57(5):773-780. 10.1053/j.ajkd.2011.01.022, 21435764.